Contrast media

Product Details:

Clariscan™ (gadoterate meglumine) injection for intravenous use
Clariscan™ ( gadoterate meglumine) is a macrocyclic gadolinium-based contrast agent, expertly manufactured by GE HealthCare, used to enhance visualization in MRI procedures across a range of indicationsABOUT CLARISCAN
As part of our comprehensive MR product portfolio, GE HealthCare is proud to offer Clariscan (gadoterate meglumine), the generic equivalent of Dotarem®. Clariscan is a macrocyclic, general-purpose GBCA used to enhance over 20 million MRI procedures globally since launch.
Clariscan is available in a range of packaging options, has a well-established tolerability profile, and is manufactured in-house by GE HealthCare. Enhanced confidence in continuity of supply and in product availability is further supported by GE HealthCare’s vertically integrated Clariscan manufacturing process.Gadoterate Meglumine: the only macrocylic, ionic molecule
Stability refers to how tightly the gadolinium ion is bound to the chelating molecule and how likely it is to dissociate. Gadoterate meglumine is the only macrocyclic, ionic molecule across all gadoliunium-based contrast agents. In vitro data suggest that combining a macrocyclic structure for high kinetic stability, with ionicity for thermodynamic stability, may help to reduce the potential risk of gadolinium dissociation.1

Product Details:

Composition :
Diatrizoate sodium salt......41.7% w/v (Diatrizoic Acid USP With sodium hydroxide IP )
In a flavoured aqueous Base.....q.s.
Iodine Content.........249.64 mg/ml
Colour : Sunset yellow FCF

INDICATIONS:
Visualization of the gastro-intestinal tract.
Early diagnosis of a radiologically undetectable perforation or anastomatic defect in the oesophagus or gasrointestinal tract.

For computerized Tomography(CT) in the abdominal region.

For ORAL use only.....not for parenteral use.

Product Details:

Jai Mata Dee Enterprises was incorporated in the year 2012 as Sole Proprietorship based firm. We are the prestigious Wholesale Trader of X-Ray Film, Pathological Products, Surgical Goods, Diagnostic Equipment and Machines, Vaccine and Total Medical Solution, etc. All our team members actively strive to meet the diverse requirements of our clients so as to achieve maximum customer satisfaction. Moreover, our products are available at industry leading prices. We possess a spacious warehouse for the safe storage of these products. Our transparent business policies have helped us in garnering a huge client base in the market.

Product Details:

Iomeron®

Iomeron® is a tri-iodinated non-ionic monomeric contrast medium for radiology7

When highest iodine concentration matters1,2,3,4,5,6Iomeron® has interesting favorable properties, such as
the lowest viscosity at given concentration among iso-osmolar contrast media (IOCM) and low-osmolar contrast media (LOCM)7;

the lowest osmolality among monomeric LOCM7;

one formulation with the highest iodine concentration (400 mgI/mL) available on the market.
An injectable solution at a higher iodine concentration allows a greater peak of enhancement in a shorter time from the injection when injected at the same volume and flow rate compared to a solution at a lower iodine concentration8.
Iomeron® (Iomeprol) is Bracco's latest generation contrast agent. Launched in 19959, this tri-iodinated non-ionic contrast agent has quickly become the preferred choice for many practicing clinicians9. Its unique and innovative profile can boast the highest concentration (400 mgI/mL), nonionic agent ever approved in the world10.
Iomeprol is currently registered in more than 40 countries worldwide, including all major European & Middle Eastern countries, Japan and the Asian Pacific. This agent represents a step forward in its class. Iomeprol has become the number one choice for many clinicians for many reasons – including:
a unique product that combines the lowest viscosity among non-ionic agents and a very low osmolality compared to other available nonionic monomeric agents10;

Iomeron® is readily available in a wide variety of iodine concentration and volumes for clinical use;

in first pass dynamic CT imaging, at equal flow rate and total iodine dose, Iomeprol 400 mgI/mL, can provide better contrast enhancement and image quality than contrast solutions at lower iodine strength11,12,13;

in a multicenter, randomized, double-blind, parallel-group comparison of Iomeron and iodxanol in coronary CTA, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for Iomeron-400 and iodixanol 32014;

a prospective intra-individual study showed that a low-dose radiation exposure acquisition protocol, in conjunction with the use of Iomeron-400, provides substantially reduced radiation exposure while maintaining a constant CNR and good image quality compared to a standard protocol using a lower concentrated contrast medium in CTA examinations15;

a large study compared the effects of Iomeprol-400 and Iodixanol-320 on kidney function in patients with pre-existing chronic kidney diseases (CKD) undergoing CT examinations. Based on the results, the authors of the study concluded: "The incidence of CIN was significantly higher after the IV administration of iodixanol-320 than iomeprol-400 in patients with moderate-to-severe CKD. The mean increase in SCr from baseline was also higher in patients receiving iodixanol. Characteristics of the individual contrast agents other than osmolality may be important in causing nephrotoxicity" 16.

Product Details: